MK 8457

Drug Profile

MK 8457

Alternative Names: MK-8457

Latest Information Update: 03 Jun 2014

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Merck & Co
  • Class Antihypertensives
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hypertension; Rheumatoid arthritis

Most Recent Events

  • 30 Apr 2014 Discontinued - Phase-I for Hypertension in USA (PO)
  • 30 Apr 2014 Discontinued - Phase-II for Rheumatoid arthritis (combination therapy) in USA, Australia, Canada, Chile, Colombia, Denmark, France, Germany, Hungary, Japan, Latvia, Lithuania, Moldova, New Zealand, Peru, Poland, South Africa, South Korea, Spain, Taiwan and United Kingdom (PO)
  • 01 Oct 2013 Merck & Co. terminates a phase II trial in Rheumatoid arthritis (combination therapy) in USA, Australia, Colombia, Denmark, France, Greece, Hungary, Italy, New Zealand, Poland, South Africa, South Korea, Spain and United Kingdom (NCT01651936; EudraCT2012-002181-12)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top